Open an account

Tenax Therapeutics

TENX · NASDAQ

$1.63+$0.11 (+7.24%)TodayMarket closed ·
Prev close $1.52

About TENX

Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company is headquartered in Chapel Hill, North Carolina and currently employs 14 full-time employees. The firm is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The firm's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The firm is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The firm has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).

Employees
14
Headquarters
Chapel Hill, North Carolina
Listed
Oct 28, 1993
Sector
Health Care
Industry
Biotechnology
Website
tenaxthera.com

TENX key statistics

Market cap
61.00M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.42M
Volume
1.33M
Open price
$1.50
High today
$1.64
Low today
$1.50
52 Week high
$19.40
52 Week low
$1.31

Tenax Therapeutics (TENX) at a glance

Tenax Therapeutics (TENX) last traded at $1.63, with a market cap of 61.00M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.50 and $1.64. The current price is 8.7% above the day's low and 0.6% below its high.

Volume so far is 1.33M shares, below the average of 2.42M shares a day.

Over the past year Tenax Therapeutics has ranged from $1.31 to $19.40, and now sits 2% of the way up that range.

Tenax Therapeutics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.35 per share against an estimate of -$0.3687.

The average analyst price target is $9.82, 502.3% above the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

50%of 8 analyst ratings say Buy
  • Buy50.0%
  • Hold50.0%
  • Sell0.0%
Price target · 10 analystsAvg $9.82
Low
$4.04
Now
$1.63
High
$36.75

TENX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 34.9% on average.

  1. Q3 FY24: reported -$0.19 per share against an estimate of -$1.42
  2. Q4 FY24: reported -$0.18 per share against an estimate of -$0.431
  3. Q1 FY25: reported -$0.28 per share against an estimate of -$0.1972
  4. Q2 FY25: reported -$0.27 per share against an estimate of -$0.2448
  5. Q3 FY25: reported -$0.40 per share against an estimate of -$0.3188
  6. Q4 FY25: reported -$0.38 per share against an estimate of -$0.4233
  7. Q1 FY26: reported -$0.35 per share against an estimate of -$0.408
  8. Q2 FY26: reported -$0.35 per share against an estimate of -$0.3687

TENX news

  • Avi Kapoor

    5 Stocks In The Spotlight From Wall Street's Most Accurate Analysts Last Month

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Press releasePRNewswire

    Tenax Therapeutics (TENX) Securities Investigation Notice - Levi & Korsinsky

  • Press releaseBusiness Wire

    TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law

  • Press releaseBusiness Wire

    TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX)

  • Press releasePRNewswire

    TENX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Tenax Therapeutics

  • Press releasePRNewswire

    Tenax Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Tenax Therapeutics (TENX)

  • Press releaseGlobe Newswire

    Tenax Therapeutics, Inc. (NASDAQ: TENX) Investors: Johnson Fistel Investigates Potential Securities Law Violations After Phase 3 Trial Failure; Shares Plummet Nearly 90%

Similar companies

Companies in the same industry as Tenax Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.